Neil F. Mcfarlane Sells 61,273 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) CEO Neil F. Mcfarlane sold 61,273 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $481,605.78. Following the sale, the chief executive officer now owns 222,060 shares of the company’s stock, valued at approximately $1,745,391.60. The trade was a 21.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Zevra Therapeutics Price Performance

Shares of ZVRA opened at $8.07 on Friday. Zevra Therapeutics, Inc. has a 1-year low of $4.20 and a 1-year high of $9.76. The stock has a market cap of $430.78 million, a PE ratio of -4.10 and a beta of 2.00. The firm has a 50-day simple moving average of $8.22 and a two-hundred day simple moving average of $8.06. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88.

Institutional Investors Weigh In On Zevra Therapeutics

Institutional investors have recently made changes to their positions in the stock. Vestal Point Capital LP purchased a new position in shares of Zevra Therapeutics in the third quarter valued at approximately $3,644,000. Sanctuary Advisors LLC purchased a new position in shares of Zevra Therapeutics in the second quarter valued at approximately $474,000. Geode Capital Management LLC boosted its stake in shares of Zevra Therapeutics by 14.2% in the third quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock valued at $7,246,000 after purchasing an additional 129,600 shares during the period. Barclays PLC boosted its stake in shares of Zevra Therapeutics by 292.6% in the third quarter. Barclays PLC now owns 57,599 shares of the company’s stock valued at $399,000 after purchasing an additional 42,926 shares during the period. Finally, Propel Bio Management LLC purchased a new position in shares of Zevra Therapeutics in the third quarter valued at approximately $1,248,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ZVRA has been the subject of several recent analyst reports. Cantor Fitzgerald upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 29th. Canaccord Genuity Group cut their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $21.57.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.